Home / News / India News / Article /
Zydus receives emergency use approval for COVID-19 drug 'Virafin'
Updated On: 23 April, 2021 12:00 AM IST | Ahmedabad | IANS
About 91.15 per cent of patients treated with the drug were RT-PCR negative by day seven, the company said in a statement.
Listen to this article :
Prime Minister Narendra Modi at Zydus Biotech Park, a vaccine manufacturing facility in Ahmedabad. Pic/INDIAN PRESS INFORMATION BUREAU / AFP
Zydus Cadila on Friday announced it has received restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of antiviral `Virafin` in treating moderate Covid-19 infection in adults.
The single dose subcutaneous regimen of the anti-viral drug reduced the need for supplemental oxygen, indicating that it was able to control respiratory distress and failure -- one of the major challenges in treating Covid-19, according to results of a multicentric trial conducted in 20-25 centres across India.
Trending Stories
Latest Photos
Latest Videos
Latest Web Stories
ADVERTISEMENT
Mid-Day Fast
ADVERTISEMENT
ADVERTISEMENT